Neuropace Share Price (NASDAQ: NPCE)

$9.15

▲

0.04

(0.44%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Neuropace Stock chart to analyse performance

Neuropace stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$8.96
Today's High:$9.16
$9.15
2.08%
Downside
Day's Volatility :2.18%
Upside
0.11%
52 Weeks Low:$5.45
52 Weeks High:$18.98
$9.15
40.44%
Downside
52 Weeks Volatility :71.28%
Upside
51.78%

Neuropace Stock Returns

Period	Neuropace Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-29.75%	3.6%	0.0%
6 Months	-22.44%	-7.7%	0.0%
1 Year	23.95%	-12.6%	0.0%
3 Years	117.06%	10.2%	-4.1%

Neuropace Inc Key Stats

Check Neuropace key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$9.11
Open	$8.96
Today's High	$9.16
Today's Low	$8.96
Market Capitalization	$301.4M
Today's Volume	$138.2K
52 Week High	$18.975
52 Week Low	$5.45
Revenue TTM	$88.6M
EBITDA	$-19.7M
Earnings Per Share (EPS)	$-0.82
Profit Margin	-29.29%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-176.94%

Stock Returns calculator for Neuropace Stock including INR - Dollar returns

The Neuropace stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Neuropace investment value today

Current value as on today

₹1,29,100

Returns

₹29,100

(+29.1%)

Returns from Neuropace Stock

₹23,816 (+23.82%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Neuropace Stock

-9%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Neuropace Stock from India on INDmoney has decreased by -9% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Neuropace Inc

Name
Holdings %
Name
Holdings %
Orbimed Advisors, LLC
10.31%
Polar Capital Holdings PLC
8.99%
Morgan Stanley - Brokerage Accounts
7.66%
Soleus Capital Management, L.P.
7.00%
First Light Asset Management, LLC
4.18%
Vanguard Group Inc
4.14%

Analyst Recommendation on Neuropace Stock

Rating

Trend

Buy

84%Buy

15%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Neuropace(by analysts ranked 0 to 5 stars)

Neuropace Share Price Target

What analysts predicted

Upside of 83.06%

Target:

$16.75

Current:

$9.15

Neuropace share price target is $16.75, a slight Upside of 83.06% compared to current price of $9.15 as per analysts' prediction.

Neuropace Stock Insights

Price Movement
In the last 3 months, NPCE stock has moved down by -30.7%
Increasing Revenue
Revenue is up for the last 8 quarters, 16.42M → 23.52M (in $), with an average increase of 5.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -5.25M → -8.65M (in $), with an average decrease of 28.4% per quarter
NPCE vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 29.0% return, outperforming this stock by 13.3%
NPCE vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 161.7% return, outperforming this stock by 46.2%
Price to Sales
ForNPCE every $1 of sales, investors are willing to pay $3.2, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Neuropace Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$37.0M	-
Net Income	$-30.0M	-
Net Profit Margin	-81.07%	-

	FY20	Y/Y Change
Revenue	$41.1M	↑ 11.27%
Net Income	$-24.3M	↓ 19.0%
Net Profit Margin	-59.02%	↑ 22.05%

	FY21	Y/Y Change
Revenue	$45.2M	↑ 9.83%
Net Income	$-36.1M	↑ 48.61%
Net Profit Margin	-79.85%	↓ 20.83%

	FY22	Y/Y Change
Revenue	$45.5M	↑ 0.75%
Net Income	$-47.1M	↑ 30.49%
Net Profit Margin	-103.43%	↓ 23.58%

	FY23	Y/Y Change
Revenue	$65.4M	↑ 43.72%
Net Income	$-33.0M	↓ 30.0%
Net Profit Margin	-50.38%	↑ 53.05%

	FY24	Y/Y Change
Revenue	$79.9M	↑ 22.14%
Net Income	$-27.1M	↓ 17.64%
Net Profit Margin	-33.97%	↑ 16.41%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$18.1M	↑ 0.62%
Net Income	$-8.9M	↑ 43.95%
Net Profit Margin	-49.24%	↓ 14.82%

	Q2 FY24	Q/Q Change
Revenue	$19.3M	↑ 6.25%
Net Income	$-7.5M	↓ 15.81%
Net Profit Margin	-39.02%	↑ 10.22%

	Q3 FY24	Q/Q Change
Revenue	$21.1M	↑ 9.37%
Net Income	$-5.5M	↓ 27.44%
Net Profit Margin	-25.89%	↑ 13.13%

	Q4 FY24	Q/Q Change
Revenue	$21.5M	↑ 1.93%
Net Income	$-5.3M	↓ 3.71%
Net Profit Margin	-24.46%	↑ 1.43%

	Q1 FY25	Q/Q Change
Revenue	$22.5M	↑ 4.93%
Net Income	$-6.6M	↑ 25.5%
Net Profit Margin	-29.25%	↓ 4.79%

	Q2 FY25	Q/Q Change
Revenue	$23.5M	↑ 4.42%
Net Income	$-8.7M	↑ 31.29%
Net Profit Margin	-36.78%	↓ 7.53%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$26.5M	-

	FY20	Y/Y Change
Profit	$30.3M	↑ 14.39%

	FY21	Y/Y Change
Profit	$33.4M	↑ 10.45%

	FY22	Y/Y Change
Profit	$32.5M	↓ 2.82%

	FY23	Y/Y Change
Profit	$48.1M	↑ 48.1%

	FY24	Y/Y Change
Profit	$59.1M	↑ 22.78%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$13.3M	↓ 1.49%

	Q2 FY24	Q/Q Change
Profit	$14.1M	↑ 5.93%

	Q3 FY24	Q/Q Change
Profit	$15.4M	↑ 9.1%

	Q4 FY24	Q/Q Change
Profit	$16.2M	↑ 4.98%

	Q1 FY25	Q/Q Change
Profit	$17.3M	↑ 7.13%

	Q2 FY25	Q/Q Change
Profit	$18.1M	↑ 4.56%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-25.0M	-
Investing Cash Flow	$3.6M	-
Financing Cash Flow	$21.4M	-

	FY20	Y/Y Change
Operating Cash Flow	$-21.6M	↓ 13.65%
Investing Cash Flow	$-10.8M	↓ 397.6%
Financing Cash Flow	$55.0M	↑ 157.41%

	FY21	Y/Y Change
Operating Cash Flow	$-24.6M	↑ 13.74%
Investing Cash Flow	$-85.4M	↑ 693.13%
Financing Cash Flow	$102.5M	↑ 86.38%

	FY22	Y/Y Change
Operating Cash Flow	$-36.9M	↑ 50.01%
Investing Cash Flow	$23.8M	↓ 127.87%
Financing Cash Flow	$490.0K	↓ 99.52%

	FY23	Y/Y Change
Operating Cash Flow	$-19.7M	↓ 46.56%
Investing Cash Flow	$23.0M	↓ 3.24%
Financing Cash Flow	$8.1M	↑ 1558.57%

	FY24	Y/Y Change
Operating Cash Flow	$-17.9M	↓ 8.89%
Investing Cash Flow	$9.0M	↓ 60.94%
Financing Cash Flow	$4.3M	↓ 46.76%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-7.5M	↑ 125.32%
Investing Cash Flow	$2.4M	↓ 30.91%
Financing Cash Flow	$72.0K	↓ 99.12%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-3.9M	↓ 48.19%
Investing Cash Flow	$3.2M	↑ 35.1%
Financing Cash Flow	$509.0K	↑ 606.94%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-1.7M	↓ 55.79%
Investing Cash Flow	$1.4M	↓ 56.75%
Financing Cash Flow	$2.9M	↑ 469.35%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-4.8M	↑ 178.25%
Investing Cash Flow	$2.0M	↑ 40.07%
Financing Cash Flow	$848.0K	↓ 70.74%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-7.5M	↑ 55.97%
Investing Cash Flow	$-37.0K	↓ 101.89%
Financing Cash Flow	$21.1M	↑ 2389.15%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-2.1M	↓ 72.12%
Investing Cash Flow	$-168.0K	↑ 354.05%
Financing Cash Flow	$-1.9M	↓ 109.04%

Neuropace Technicals Summary

Sell

Neutral

Buy

Neuropace is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Neuropace Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Neuropace Inc	1.89%	-22.44%	23.95%	117.06%	-63.3%
Medtronic Plc	3.87%	-1.59%	4.32%	4.82%	-13.69%
Edwards Lifesciences Corp.	2.55%	13.95%	18.33%	-9.73%	-5.31%
Boston Scientific Corp.	0.09%	0.6%	30.02%	157.38%	154.4%
Stryker Corporation	3.63%	-0.85%	8.87%	89.43%	97.71%
Abbott Laboratories	4.24%	-5.37%	15.72%	26.56%	24.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Neuropace Inc	NA	NA	NA	-0.85	-1.77	-0.12	NA	0.59
Medtronic Plc	25.4	25.4	2.14	5.46	0.1	0.05	0.03	37.36
Edwards Lifesciences Corp.	34.03	34.03	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.95	62.95	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.54	51.54	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.64	16.64	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Neuropace Inc	Buy	$301.4M	-63.3%	NA	-29.29%
Medtronic Plc	Buy	$118.0B	-13.69%	25.4	13.63%
Edwards Lifesciences Corp.	Buy	$47.8B	-5.31%	34.03	72.96%
Boston Scientific Corp.	Buy	$156.7B	154.4%	62.95	13.55%
Stryker Corporation	Buy	$149.0B	97.71%	51.54	12.25%
Abbott Laboratories	Buy	$230.9B	24.53%	16.64	32.43%

About Neuropace Inc

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Organization	Neuropace
Employees	209
CEO	Mr. Joel D. Becker
Industry	Healthcare

Key Management of Neuropace Inc

Name	Title
Mr. Joel D. Becker	CEO, President & Director
Dr. Martha J. Morrell M.D.	Chief Medical Officer
Ms. Rebecca L. Kuhn	Advisor
Mr. Patrick F. Williams	Chief Financial Officer
Mr. Dylan St. John	Chief of Operations & Development
Ms. Leah Akin	General Counsel & Corporate Secretary
Ms. Katie Keller	Vice President of Marketing
Mr. Chris Reese	Senior Vice President of Sales
Ms. Amy Treadwell	Vice President of Human Resources

Important FAQs about investing in NPCE Stock from India :

What is Neuropace share price today?

Neuropace share price today is $9.15 as on August 30, 2025 at 1:29 am IST at the close of the market. Neuropace share today touched a day high of $9.16 and a low of $8.96.

What is the 52 week high and 52 week low for Neuropace share?

Neuropace share touched a 52 week high of $18.98 and a 52 week low of $5.45. Neuropace stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $9.15, lower by 51.78% versus the 52 week high.

How to invest in Neuropace Stock (NPCE) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Neuropace on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Neuropace Shares that will get you 0.1639 shares as per Neuropace share price of $9.15 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Neuropace Stock (NPCE) from India?

Indian investors can start investing in Neuropace (NPCE) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Neuropace stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Neuropace share’s latest price of $9.15 as on August 30, 2025 at 1:29 am IST, you will get 1.0929 shares of Neuropace. Learn more about fractional shares .

What are the returns that Neuropace has given to Indian investors in the last 5 years?

Neuropace stock has given -63.3% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?